Blair William & Co. IL trimmed its stake in shares of Doximity, Inc. (NASDAQ:DOCS - Free Report) by 47.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,683 shares of the company's stock after selling 23,951 shares during the period. Blair William & Co. IL's holdings in Doximity were worth $1,425,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DOCS. Handelsbanken Fonder AB raised its stake in shares of Doximity by 0.7% in the 4th quarter. Handelsbanken Fonder AB now owns 29,700 shares of the company's stock valued at $1,586,000 after purchasing an additional 200 shares during the period. UMB Bank n.a. raised its position in Doximity by 69.1% in the 4th quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after buying an additional 235 shares during the last quarter. Fielder Capital Group LLC raised its position in Doximity by 4.5% in the 4th quarter. Fielder Capital Group LLC now owns 5,488 shares of the company's stock valued at $293,000 after buying an additional 235 shares during the last quarter. Larson Financial Group LLC lifted its stake in Doximity by 49.4% in the 4th quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after acquiring an additional 250 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in Doximity by 20.6% during the 4th quarter. GAMMA Investing LLC now owns 1,735 shares of the company's stock worth $93,000 after acquiring an additional 296 shares during the last quarter. 87.19% of the stock is owned by institutional investors and hedge funds.
Doximity Stock Performance
Shares of DOCS stock traded up $0.99 during midday trading on Monday, hitting $52.23. 3,333,126 shares of the company were exchanged, compared to its average volume of 1,959,486. Doximity, Inc. has a 52 week low of $22.96 and a 52 week high of $85.21. The firm has a market capitalization of $9.75 billion, a P/E ratio of 52.23, a PEG ratio of 4.10 and a beta of 1.41. The firm's 50 day moving average price is $65.43 and its two-hundred day moving average price is $55.21.
Insiders Place Their Bets
In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now owns 6,360 shares in the company, valued at $366,463.20. This trade represents a 75.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 37.40% of the company's stock.
Analyst Ratings Changes
A number of analysts have recently commented on DOCS shares. Wells Fargo & Company reissued an "equal weight" rating on shares of Doximity in a research report on Friday, February 7th. Needham & Company LLC boosted their price target on shares of Doximity from $65.00 to $82.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Stephens initiated coverage on Doximity in a report on Friday, December 20th. They issued an "equal weight" rating and a $55.00 price objective for the company. The Goldman Sachs Group increased their price target on Doximity from $58.00 to $80.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Leerink Partnrs raised Doximity from a "hold" rating to a "strong-buy" rating in a research report on Friday, February 7th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $64.22.
Read Our Latest Research Report on DOCS
Doximity Company Profile
(
Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
See Also
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
